# Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

> **NCT06613217** · PHASE1 · RECRUITING · sponsor: **Pacylex Pharmaceuticals** · enrollment: 35 (estimated)

## Conditions studied

- Relapsed Adult AML

## Interventions

- **DRUG:** zelenirstat

## Key facts

- **NCT ID:** NCT06613217
- **Lead sponsor:** Pacylex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613217, "Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06613217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*